BioCurex Announces Filing of New Patent For Cancer Diagnostics, Therapeutics Based on its Proprietary RECAF Technology

08-Nov-2010 - Canada

BioCurex Inc. announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.

The subject of this patent is a synthetic peptide that recognizes RECAF™ and that can replace the antibodies used in BioCurex's RECAF test. The synthetic peptide also allows for many other applications that cannot be performed with an antibody. BioCurex's patent application contains over 50 claims covering different applications and uses of this peptide.

'This is one of our most significant technical advancements since the RECAF cancer test was announced,' said BioCurex CEO and President Dr. Ricardo Moro-Vidal. 'The product of several years of work, this patent will improve everything we do while reducing the complexity and cost of the process. Most importantly, the granting of this new patent application will extend the life of our current patents by two decades. Furthermore, this peptide opens a wide range of possibilities for delivering killing agents to cancer cells.'

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous